Pfizer advances Litfulo for vitiligo in face of Incyte and AbbVie competition on July 30, 2026 AbbVie Incyte Janus kinase inhibitor LITFULO Opzelura Pfizer Phase 3 regulatory filings Rinvoq Ritlecitinib Vitiligo +
AbbVie scores dual EU approvals for Rinvoq in vitiligo, alopecia on July 30, 2026 AbbVie Adolescent (age group) Adult Alopecia Approved CHMP EU European Commission approval older Opinions Positive Rinvoq Severe (severity modifier) systemic treatment upadacitinib Vitiligo +
AbbVie Scores First Rinvoq Alopecia Nod in EU on July 29, 2026 AbbVie Alopecia Approved CHMP Commission EU European (ethnic group) Janus kinase inhibitor Phase 3 Rinvoq SALT score Severe (severity modifier) systemic treatment UP-AA +
AbbVie Extends Rinvoq Exclusivity to 2037, Delaying Generics in U.S. on September 12, 2025 AbbVie exclusivity extension Generic Competition Market patent settlement pharmaceutical litigation Rinvoq U.S. upadacitinib +
AbbVie's Rinvoq Achieves Second Phase 3 Win in Alopecia Areata Trials on August 22, 2025 AbbVie Alopecia Eyebrow structure Eyelash hair regrowth Rinvoq safety profile Salts Score upadacitinib +
AbbVie's Rinvoq Achieves Strong Phase 3 Results in Alopecia Areata, Clearing Key Efficacy Milestone on August 22, 2025 AbbVie Alopecia hair regrowth Inhibitor Janus kinase Rinvoq Salts Score upadacitinib +
AbbVie's Rinvoq cleared for giant cell arteritis in US on April 30, 2025 Approved Giant Cell Arteritis Inhibitor Janus kinase Rinvoq Steroids United States Food and Drug Administration upadacitinib +